A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation

Abroad (travel likely)RecruitingPHASE1

Conditions

Solid Tumors Harboring a TP53 Y220C Mutation

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhongshan Hospital ,Fudan University, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Tianshu Liu, Doctor) · +8613681973996
liu.tianshu@zs-hospital.sh.cn

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

TP53 Y220C Mutation · Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Denver, United States · Orlando, United States

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Denver, United States · Lake Mary, United States